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Abstract
Over the years, anti-cancer therapies have improved the overall survival rate of patients.
Nevertheless, the traditional free drug therapies still suffer from side effects and systemic toxicity,
resulting in low drug dosages in the clinic. This often leads to suboptimal drug concentrations
reaching cancer cells, contributing to treatment failure and drug resistance. Among available anticancer therapies, metallodrugs are of great interest. Platinum (II)-based agents are highly potent
and are used to treat many cancers, including ovarian cancer (OC). Cisplatin (cisdiaminedichloroplatinum (II)) is the first Food and Drug Administration (FDA)-approved
metallodrug for treatment of solid tumors, and its mechanism of action is based on inhibition of
cancer cell replication via binding to nuclear DNA. However, circulating cisplatin binds to
glutathione and other proteins in the blood compartment, diminishing the concentration of the free
drug available for therapy. Also, highly potent cisplatin is associated with severe side effects,
limiting the dosage of Pt(II) that can be administered in the clinic. The next generation Pt(II) drugs
aim at sustaining the same effectiveness while improving systemic toxicity. Carboplatin is a
second-generation Pt-based agent approved by the Food and Drug Administration (FDA). Slower
hydrolysis times for carboxylate ligands in carboplatin, compared to rather fast times for chlorine
ligands in cisplatin, lead to longer blood circulation times and lesser side effects. The therapeutic
effect of carboplatin is comparable with cisplatin in some tumors, but it requires higher drug
dosages, and the survival rate did not improve.
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The problems above associated with free Pt(II)-based therapy created a need for the
development of more efficient drug delivery systems. These include targeted drug delivery such
as an antibody or protein conjugates or nanoparticle (NP)-mediated drug delivery, e.g., by using
liposomes, polymeric or oil-based NPs, among other approaches. This dissertation presents two
alternative drug delivery systems for Pt(II)-based agents: peptide conjugate and a NP. These
systems are tested in OC models, where Pt (II) therapy is a golden standard.
Chapter II focuses on a peptide-drug conjugate of nuclear localization sequence (NLS)
peptide-carboplatin-like complex. Nuclear localization sequence peptides target nuclear transport
protein, delivering the therapeutic payload into a cancer cell's nucleus. NLS-Pt(II) conjugate
demonstrated enhanced therapeutic effect in vitro in OC cell lines when compared to carboplatin.
Conjugation of carboplatin-like complexes with NLS peptide also drastically increased the
solubility of Pt(II) drug in an aqueous media.
Chapter III focuses on targeted and pH-sensitive polymeric NP to deliver Pt(II). Poly lacticco-glycolic acid (PLGA)-based NPs are explored, as the PLGA is biodegradable, biocompatible,
and, most importantly, approved by the FDA. The NP's corona contains phospholipids and customsynthesized pH-sensitive polyethylene glycol (PEG)-phospholipid coating. A DNA-aptamer
against mucin 1 (MUC1), which is overexpressed in OC cells, is added as an active targeting
ligand. The NP design takes advantage of a slightly acidic environment around cancer cells
(pH~6.8) to disintegrate PEG-based NP's coating and to expose the aptamer targeting ligands
facilitating a fast NP uptake through receptor-mediated endocytosis. Slow intracellular
degradation of the NP leads to sustained release of Pt(II). The NPs showed higher cytotoxicity in
vitro when compared to free carboplatin, and the NPs effectively accumulated in the tumor tissue
in vivo. Importantly, the NP platform can be easily modified. The ease of functionalization of
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PLGA with other drugs, as well as the choice of different targeting aptamers, can extend the
applications of the proposed NP platform to other disease types.
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4. CHAPTER I. DRUG DELIVERY SYSTEMS
4.1 Background and significance
Cancer is the second most common cause of death in the United States, surpassed only by
cardiovascular disease, accounting for nearly one in every four deaths. The number of new cancer
cases per year is expected to rise to 23.6 million by 20301. In 2021, an estimated 1,898,160 new
cancer cases were diagnosed in the United States, and 608,570 people will die from the disease
(International Agency for research of cancer)2. Ovarian cancer (OC) is one of the leading causes
of death among women, mainly due to the late-stage detection of the disease3. The standard OC
therapy includes surgical removal followed by treatment with Pt (II)-based drugs or Pt (II)
combination therapy with other antineoplastic agents, e.g., paclitaxel4.
The nanoparticle (NP)-mediated delivery systems have been extensively studied to aid
cancer therapy. It is well documented that NPs can encapsulate toxic or hydrophobic drug
molecules, thus minimizing systemic toxicity and achieve targeting5. The accumulation of NPs in
the tumor's interstitium is caused by the tumor's leaky vasculature and so-called enhanced
permeability and retention (EPR) effect, where the NPs extravasate through a defective vascular
system into the tumor’s interstitium6. The accumulation of NPs in the tumor via EPR, also known
as passive targeting, depends strongly on the NP's size, and a suitable diameter of the NP to
facilitate tumor’s targeting via EPR is ~100 nm. Although very promising, the NP-mediated drug
delivery via EPR results only in about 0.7% of the drug retained in the tumor7. To increase the
NPs uptake by cancer cells ensuring that most tumor accumulated NPs enter cancer cells for
maximum efficacy, active targeting strategies can be incorporated into NP designs8. Active
targeting is based on the addition of ligands to the NPs’ surface that recognize complementary
cellular receptors, usually a surface protein overexpressed on cancer cells.
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There are several different types of NP carriers suitable for drug delivery. Most common
include micelles, liposomes, dendrimers, antibody conjugates, carbon nanotubes, metallic NPs,
protein conjugates, and most importantly, polymeric NPs8. Initially, polymeric NPs were
synthesized with non-biodegradable polymers such as polystyrene and polyethylene glycol
(PEG)9-10. Currently, biocompatible polymers are being explored, including polylactic-co glycolic
acid (PLGA)11. PLGA is biocompatible, biodegradable, and, most importantly, FDA approved12.
Therefore, it is readily used for various medical applications, including biodegradable bone
implants, grafts, sutures, or surgical sealants13. These properties also make PLGA a suitable
material for NP formulations and drug applications.
Cisplatin (cis-diaminedichloroplatinum (II)), the first-generation Pt (II)-based agent, was
approved by the FDA in 1978 for cancer therapy14. Cisplatin is a cytotoxic agent that activates
within the cell to form [Pt(NH3)2]2+ species upon hydrolysis of chlorine ligands. Cisplatin binds to
N-7 of guanine or adenine and forms a 1,2 or 1,3 intrastrand crosslink within DNA, inhibiting
DNA replication15. The major shortcoming of cisplatin is premature activation in the bloodstream,
which induces severe side effects and systemic toxicity, limiting the maximum dosage that can be
used in the clinic16. Besides, binding of Pt (II) to plasma proteins further diminishes the
concentration of Pt (II) capable of entering cancer cells. This often leads to insufficient DNA
damage, followed by cellular DNA repair, and acquired Pt (II) resistance by cancer cells17. The
ultimate recurrence of cancer contributes to low overall survival rates among patients18.
To overcome the negative effect of early activation of cisplatin, second-generation Pt (II)
analogs have been developed. The goal was to diminish the side effects of Pt (II) while increasing
the dosage. These include carboplatin, oxaliplatin, heptaplatin, nedaplatin, and lobaplatin19. All
second-generation Pt (II) drugs possess lower toxicity profiles compared to cisplatin, which is
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attributed to slower hydrolysis of carboxylate chelates compared to chlorides. However, the dose
escalation is minimal, and the crucial problem of Pt (II) resistance remains, thus the effectiveness
of therapy with second-generation Pt(II) agents remains unchanged20.
Currently, additional Pt (II) analogs undergo clinical trials, such as Lipoplatin and Lipoxal,
as well as liposomal cisplatin and oxaliplatin21-22. Also, combination therapies with drugs targeting
different metabolic pathways or different mechanisms of action are being explored. The
cumulative effect of combination therapies is often a better patient survival profile23.
Another example of an innovative approach to Pt-based therapy is exploring Pt (IV)
complexes, e.g., satraplatin, that rely on Pt (IV) reduction to Pt (II) within the bloodstream.
Satraplatin, currently in clinical trials in the US, can be administered orally instead of
intravenously, which is more convenient to patients and more cost-effective24. Although Pt-based
drugs are still leading therapies of choice, some new promising metalorganic molecules are
emerging. These include ruthenium, gold25, gallium, and also arsenic analogs. Among the most
promising are NAMI-A, KP1019, BOLD-100, AP-002, and Darinaparsin26-27. AP-002 currently
undergoes Phase 2 clinical trial for treatment of solid tumors, such as recurrent breast cancer, nonsmall cell lung cancer and prostate cancer28. BOLD-100 is in Phase 1 clinical trial for the treatment
of colorectal, pancreatic, and gastric cancers as well as in combination with FOLFOX29 for
cholangiocarcinoma therapy. Most of the modern metallodrugs are organometallic compounds and
have limited solubility in water (Figure 1). Attempts to incorporate them into more sophisticated
drug delivery systems are being investigated. The anti-cancer applications of organometallic drugs,
although very promising, are still in their early stages. The development of new classes of
organometallic compounds is on the rise30. Figure 1. shows the respective structures of the
metallodrugs.
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Auranofin

BOLD-100

AP-002

Figure 1. Metallodrugs used in the clinic (top) and examples of metallodrug candidates (bottom).
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4.2 Nanoparticle drug delivery systems.
NP-based drug delivery systems are of particular interest as they can aid the current search
for more effective cancer therapies. Over the years, several different platforms have been
developed, and the main groups include liposomes, micelles, nanoemulsions, inorganic NPs, and
polymeric NPs30, which are schematically shown in Figure 2.

Figure 2. Schematic representation of NP-based delivery carriers.

4.2.1 Liposomes: the Liposome is the first-generation NP system, where a phospholipid bilayer
surrounds an aqueous core31. Liposomes encapsulate hydrophilic molecules in the aqueous
core and hydrophobic molecules within the bilayer. Different liposomal formulations are
currently undergoing clinical trials or are FDA approved and used in the clinic. Among the
latter, Doxil32 is a liposomal formulation of doxorubicin used to treat various solid tumors.
Marqibo is liposomal vincristine used in leukemia, lymphoma, or melanoma33. Also, a
liposomal irinotecan with a brand name Onivyde MM-398 is used in the therapy of
5

metastatic pancreatic cancer34. However, the disadvantages of liposomes include fast drug
release (burst release) as well as inducing an immune response35.
4.2.2 Micelles: Micelles are simple NPs assembled from amphiphilic molecules. The
hydrophobic side of the amphiphilic molecule comprises the core, while the hydrophilic
side is exposed to the aqueous media. The combination therapies with micellar
formulations of paclitaxel and doxorubicin are in pre-clinical trials in therapies of breast
and colorectal cancers. Similar to liposomes, micelles have characteristic burst drug release
and often premature release resulting from fast structural disintegration in an aqueous
environment35.
4.2.3 Inorganic NPs: Inorganic NPs are most commonly used as contrast agents. Inorganic iron
oxide and hafnium oxide NPs are also being used in current anti-cancer thermal/radio
therapy36. More elaborate designs consist of inorganic NPs embedded in a polymer or
inorganic mesoporous material and active drug with or without the targeting ligand. For
example, iron oxide NPs, loaded with camptothecin and coated with silica gel, propylmethyl phosphonate, and folic acid were used in the pancreatic cancer cell model37.
Peptide-coated gold NPs were successfully used to inhibit or activate a blood vessel
formation38. Also, platinum NPs coated with H-Lys-Pro-Gly-Lys-NH2 exhibited superior
selectivity and toxicity to hepatic cancer cells (HepG2) when compared to cisplatin39. The
major drawback of using metallic NPs as drug carriers arises from their lack of
biocompatibility and premature drug release. There is also a question of inorganic NPs
long-term systemic toxicity and accumulation in the body40.
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4.2.4 Polymeric NPs: Another large group of NPs used in drug delivery comprises polymeric
NPs41. The examples include polystyrene, chitosan, or PLGA NPs, among others.
Polystyrene NPs are stable, can be synthesized in various sizes with low polydispersity,
and are easy to functionalize. However, they are not biodegradable, which limits their
potential clinical use10. Still, they are readily used in model studies of the NP interactions
with cells, proteins, and other biological components42.
PLGA NPs are second-generation NPs capable of fine-tuning drug release that can
sharply increase the efficacy of therapy. Currently, PLGA conjugated microspheres, such
as Trelstar43 and Lupron Depot44, are clinically used to treat prostate cancer. PLGA is a
polyester composed of lactic and glycolic acid subunits and is fully biodegradable and
biocompatible. PLGA is highly hydrophobic, thus, suitable for incorporating hydrophobic
drug molecules. PLGA NPs encapsulating anti-cancer drugs e.g., cisplatin, doxorubicin,
paclitaxel, as well as contrast agents e.g. fluorophores or gold nanocrystals have been
proposed45-46.
PLGA NPs are usually stabilized with surfactants, such as polysaccharides
phospholipids, polyethylene glycol (PEG), or PEGylated phospholipids45. Among these,
PEG is the most widely used in NP formulations creating a stable coating around the NP
in aqueous media due to its hygroscopic properties. As a result, PEGylated NPs are hidden
from the mononuclear phagocyte system (MPS) in the blood compartment, allowing long
NP circulation times47. On the contrary, steric hindrance caused by PEG leads to
suppressed cellular uptake of PEGylated NPs and their endosomal escape. This
phenomenon is known as the "PEG dilemma" and often complicates NP-mediated drug
delivery to cancer cells48.
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4.3 Aptamers as targeting ligands:
Commonly used active targeting ligands include antibodies, short peptides, foliates,
glycosides, and recently DNA aptamers49. DNA aptamers are short oligonucleotides, usually 1570 bp, which gained much attention due to their superior target recognition characteristics that
rival even those of antibodies50. Aptamers bind to their corresponding ligands via noncovalent
interactions, such as hydrophobic forces and electrostatic interactions. The shape of the aptamer
plays a crucial role in molecular recognition. Typical targets for aptamers include proteins,
molecules, nucleic acids, and cells. They are non-immunogenic, biocompatible, and
biodegradable. Unlike antibodies, aptamers are much smaller in size and can be synthesized to
order51. The whole selection process can be completed within three days. It is scalable and more
cost-efficient when compared to antibodies52. Figure 3 shows the schematic structure of an aptamer
and its binding to the cellular target52.

Figure 3. Schematic of a DNA aptamer and its binding to target protein expressed on the cell’s
surface.
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However, the major drawback of aptamers is their short half-life in vivo caused by
enzymatic degradation, limiting their biological applications53. Aptamers are easy to modify and
functionalize with other molecules like phospholipids or PEG and, importantly, can be
incorporated into the NP's corona. The latter can initiate the receptor-mediated endocytosis of the
NPs and dramatically increase the NP internalization by cancer cells, thus heighten the NP's
retention in the tumor50.
The aim of this project is to address the shortcomings of a free Pt (II) therapy, using a
second-generation PLGA NP platform to encapsulate carboplatin like Pt (II) complex. The NP
design includes active targeting ligand – an aptamer against Mucin 1, which is a protein
overexpressed in OC cells. The active targeting approach in the NP is used with a pH-sensitive
surface shielding technology based on phospholipid-PEG synthesized with an acid-labile linker.
PEG chains shield the aptamer ligands on the NP's surface at physiological pH, and disintegrate at
lower pH exposing the ligands. This can enhance the NP uptake by cancer cells via receptormediated endocytosis and increase the NP retention in the tumor, eventually leading to improved
therapeutic outcomes.
4.4 Formulation of PLGA NPs.
Emulsification-Evaporation method: It is the most commonly used method for PLGA
NP synthesis. In this method, the active ingredient is usually dissolved in a volatile organic solvent
and added to a surfactant-containing aqueous solution while stirring. Once completed, the organic
solvent is evaporated, and emulsion forms. The emulsion can be used as is, or the process can be
repeated several times to achieve double or multiple emulsions. However, the concentration of the
polymer has to be strictly controlled. The size of NPs depends on the polymer concentration in the
evaporation step54-55.
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Salting out method: In this method, both PLGA polymer and a drug are dissolved in an
organic solvent miscible with water. An organic solution is added to an aqueous solution
containing salt and surfactant. The NPs form while organic solvent dissolves in aqueous media.
This method is very convenient if components are temperature sensitive, as it can be performed at
room temperature. However, it requires extensive purification steps to remove residual
surfactants54-55.
Microfluidics-assisted method: Microfluidic method allows for the continuous synthesis
of NPs. Organic solutions containing PLGA polymer and drug, as well as an aqueous solution
containing surfactants, are transferred via micro channels into a mixing chamber where NPs
synthesis occurs. The NPs synthesized by this method have a more narrow size range, compact
morphology, and a high level of reproducibility. This is attributed to strictly controlled solvent
flow rate, temperature, and reaction time56-57. The schematic approach to each nanoparticle method
is shown in Figure 4.
Nanoprecipitation method: It is a single-step procedure where polymer and drug
dissolved in an organic solvent are added dropwise into an aqueous solution containing
surfactant/s. Phospholipids and PEGylated phospholipids may serve as stabilizing agents. This
method is easily scalable. The NP size depends on polymer-surfactant ratio, PLGA molecular
weight, the chemical nature of the solvent as well as the stirring rate. Afterward, the product is
washed several times to remove residual surfactants. This method's simplicity allows for easy
surface modification and purification of the synthesized NPs54-55. The nanoprecipitation method
was used in this work to synthesize pH-sensitive PLGA NPs for Pt(II) delivery.
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Figure 4. Schematic representation of the NP synthesis method58-60.
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5. CHAPTER II. NUCLEAR LOCALIZATION SEQUENCE PEPTIDE AS A
PLATINUM(II) DRUG CARRIER
5.1 Introduction
Nuclear localization sequence (NLS) peptides target nuclear transport. Importins α and β
facilitate the transport of proteins or DNA into the nucleus. Proteins containing NLS sequence
bind to importin α active sites and then to the importin β. Interaction of importin β with nuclear
pore complex enables nuclear transport of importin α complex into the nucleus and release of its
cargo protein. The first the NLS peptide, with PKKKRKV sequence, was discovered in SV40
Large T-Antigen. This peptide has demonstrated an excellent ability to transfer SV40 Large Tantigen into the nucleus and has been used as a model study for NLSs. The PKKKRKV sequence
is of viral origin and belongs to the monopartite family of NLSs, indicating only one continuous
peptide sequence. Other bipartite NLSs possess two separate peptide sequences separated by a
short spacer sequence. Bipartite NLS peptides are predominant localization sequences found in
cellular nuclear proteins.
Since their discovery, the platinum (II) based drugs (Figure 1) are leading compounds of
choice in many cancer therapies. Cisplatin, cis-diamminedichloroplatinum(II), is the first platinum
(II) medication approved by the FDA for anticancer treatment15,

19, 61

. Other FDA-approved

platinum (II) drugs include carboplatin and oxaliplatin. There are also additional platinum drugs
that are awaiting FDA approval or are already in use outside the US19. The overall survival rates
of patients treated with any Pt-based complex are comparable. Cisplatin, carboplatin, and
oxaliplatin share a structural feature, where amine ligands are coordinated to the central platinum
atom. However, the remaining two ligands are varied in the complexes. In cisplatin, there are two
chlorides coordinated to platinum, while carboplatin and oxaliplatin have carboxylate ligands. In
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both cases, the drug must possess a cis configuration to present high efficacy. Transplatin, with
trans configuration, is much less potent compared to cisplatin.
The mechanism of action of platinum compounds involves an initial hydrolysis of either
chlorine or carboxylate ligand, leading to the formation of active [Pt(NH3)2L(H2O)]+ species that
enter the nucleus via electrostatic interactions to negatively charged DNA. Activated cisplatin
forms covalent DNA adducts between intrastrand 1,2d (GpG) and 1,3d (GpXpG), as well as
interstrand G-G cross-links. The platinum-induced changes lead to DNA shape distortion, resulting
in inhibition of the cellular replication and transcription processes. Once the damage to DNA is
beyond repair, the cell induces apoptosis62-64.
However, although highly potent, the Pt-based therapy also results in systemic toxicity,
which varies for different complexes and is dependent on the ligands coordinated to the Pt (II)
center. Cisplatin induces higher systemic toxicity compared to carboplatin and oxaliplatin due to
its high aquation rates and formation of active Pt(II) species in the circulation, which can affect
healthy cells65. Therefore, lower drug concentrations have to be used therapeutically. In addition,
the activated cisplatin in circulation forms irreversible complexes with molecules containing free
thiol –SH, and reversible complexes with -SCH3, affecting glutathione, metallothionein, and
methionine. Sulfur coordinated platinum complexes are unable to interact with DNA due to
increased stability of S-Pt bond, diminishing their effectiveness. In addition the Pt complexes bind
to plasma proteins. Those interactions inhibit the therapeutic activity of cisplatin, decreasing its
efficacy. As a result, subtherapeutic concentrations of cisplatin may reach the cancer cell nucleus,
causing lower DNA damage and activation of DNA repair pathways, contributing to the
development of subsequent drug chemoresistance66-67.
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Oxaliplatin and carboplatin have lower aquation rates, as carboxylate ligands coordinated
to platinum are more resistant to hydrolysis as compared to chlorides in cisplatin64, 68-70. Therefore,
these complexes are characterized by lower systemic toxicity. Also, the shelf life of aqueous
solutions of carboplatin is longer when compared to cisplatin. Only about 3% of carboplatin
decomposed after 150 days of storage in aqueous media70. Ideally, the activation of the Pt-based
complexes should occur in the cytoplasm, then [Pt(NH3)2L(H2O)]+ complex should enter the
nucleus and interact with the DNA. One drawback of Pt (II) complexes with carboxylate ligands
is slow hydrolysis in the cytoplasm, which delays the formation of active Pt (II) species and slows
down the nuclear entry, eventually lowering the efficacy of the drug. To address this problem,
thousands of platinum complexes have been reported for over forty years, but only a few have
entered clinical trials. Thus, the need for developing a new class of platinum compounds is of high
importance. The lower systemic toxicity, higher drug efficacy, and better solubility under
physiological conditions are the key factors that need to be improved in Pt-based therapy71-72.

5.2 Synthetic strategy
Short peptides are increasingly explored for therapeutic applications, and currently, over a
hundred peptide-based therapies are undergoing clinical trials. Short peptides are among the large
group of targeting ligands employed in the fight against cancer. Other systems include Pt (II)
conjugates with folate receptors73, angiogenic receptors74, liver and estrogen receptors75-76.
Glucose conjugates have also been explored to target the high nutritional demand of cancer cells77.
Previously reported peptide conjugates with platinum employed mainly Pt (IV) prodrugs and a
limited number of Pt (II) conjugates. PEG-Pt-NLS conjugates were also reported with moderate
therapeutic efficacy78-84.
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Our approach focuses on the formation of PKKKRKV peptide hybrid with Pt (II)
complexes. NLS peptides usually possess a high concentration of hydrophilic amino acids in their
sequence. A high presence of arginine and lysine amino acids in PKKKRKV makes the NLS
peptide highly water-soluble. It also gives it a positive charge under physiological conditions,
required for successful interaction with integrin α and nuclear membrane transport85-86. The goal
is to conjugate carboplatin-like complexes with NLS peptide to solve two significant problems
associated with the use of carboplatin. Firstly, we aim to provide the ability for targeted transfer
of unchanged Pt (II) complex into the nucleus. Secondly, we focus on a significant increase in the
solubility of the drug.
The original approach to form the Pt(II)-NLS hybrid employed the synthesis of new
carboplatin-like complexes that have linkers available for chemical reactions. To this end, azide
Pt(II)-N3 (C10H21N5O4Pt) and an alkyne Pt(II)-CCH (C10H18N2O4Pt) complexes were synthesized
in a multistep organic synthesis, which is explained in Experimental Section. The goal was to
conjugate our new complexes functionalized with alkyne or azide to NLS peptide via a click
reaction, as presented in Figure 5.
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B

C

Figure 5. Chemical structure of platinum (II) complexes Pt(II)-N3 (A), and Pt(II)-CCH (B), and
the structure of the Pt-NLS conjugate (C).
However, the Pt-azide and Pt-alkyne complexes do not dissolve in water and, although the
complexes are promising for organic solvent-based approaches, the conjugation to NLS peptides
was difficult. Therefore, we employed the new synthetic pathway, which is shown in Figure 6, to
form the Pt-NLS hybrid. In the first step, the NLS peptide was conjugated with dicarboxylate
ligand via copper-catalyzed click reaction during solid-phase peptide synthesis. In the second step,
the dicarboxylate-NLS ligand was purified and conjugated with diamine platinum. This strategy,
which involved the formation of the Pt (II) complex directly on the peptide, was successful and
resulted in a stable, highly soluble Pt-NLS hybrid that was further explored for therapeutic
purposes. The full description of the synthetic strategy is included in the Experimental Section.
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Figure 6. The new approach to Pt-NLS synthesis. Peptide 1 reacts with activated
diaminediaquaplatinum (II) to form peptide 2 (Pt-NLS).

5.3 Density Functional Theory (DFT) analysis and characterization of the products.
Azide and alkyne complexes, as well as Pt-NLS hybrid, were analyzed by the FT-IR.
Experimental spectra were compared to the density functional theory (DFT) calculated spectra87.
Vibrations, characteristic for several functional groups present in all complexes, were detected,
and azide and alkyne functionalities present in Pt(II)-N3 and Pt(II)-CCH were identified. An
overlay for the computed and experimental spectra is presented in Figure 7. The N═N═N and the
C≡C stretching vibrations are observed as an intense signal at 2095 cm–1 (frame A) and weak
signal at 2111 cm–1 (frame B), respectively. The IR bands around 1320 and 1600 cm–1 are assigned
to the C=O stretching. The experimental spectra for the complexes are in good agreement with
DFT predicted data.
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Figure 7. Experimental and calculated IR spectra of Pt (II) complexes; Pt(II)-N3 complex (section
A), Pt(II)-CCH complex (section B), and Pt-NLS hybrid (section C).
The IR spectrum of Pt-NLS conjugate (frame C) shows characteristic amide I, II, III bands
at 1642 cm–1, 1542, and 1338 cm–1, respectively, and they are also in agreement with those
obtained by the DFT study. DFT spectra overemphasized the intensities of C═O stretching at
around 1600 and 1450 cm–1, most likely due to the C═O proximity and coordination to Pt (II) that
enhances electron polarizability in an analyzed model, thus over stimulating computed intensities.
Characteristic deformations for the Pt (II) complex are found at lower frequencies of 900–700 cm–
1

. Those frequencies are specific to a six-member ring present in all characterized complexes and

Pt-NLS conjugate. DFT calculations were performed by Dr. Andrzej Jarzecki from Brooklyn
College.
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The complexes and the hybrid were also analyzed by High Resolution Mass Spectrometry
(HRMS), and the results are presented in Experimental Section (Figure 8). The data clearly
demonstrate that isotopic distributions are in agreement with the theoretical values. The exact
masses of the complexes are as follows: Pt(II)-N3 complex is 470.1241 au, and of the Pt(II)-CCH
complex is 425.0914 au; the Pt-NLS hybrid is 1447.7865 au. As mentioned before, the solubility
in aqueous media of the alkyne and azide complexes was very low. However, the new synthesis
strategy that was based on forming the complexes directly on the NLS peptide resulted in highly
enhanced solubility of Pt (II) via conjugation to the peptide. The solubility of Pt-NLS was found
to be over 50 mg/ml or 35 mM. Importantly, enhanced solubility of Pt (II) through NLS peptide
addresses one of the major concerns associated with the bioavailability of platinum-based therapy.
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Figure 8. HRMS of Pt-NLS hybrid (section A),Pt(II)-N3 complex (section B), Pt(II)-CCH complex
(section C).
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5.4 Rationale and biological evaluation of new Pt(II)-NLS hybrid.
As mentioned before, NLS peptides have a unique ability to penetrate cellular and nuclear
membranes. DNA or small proteins can be carried into the cytoplasm and then to the nucleus with
the assistance of the NLS peptides. PKKKRKV peptide belongs to the well-known group of short
peptides with the ability to carry DNA or small proteins into the cytoplasm and nucleus88-89. To
confirm the penetrating properties of the PKKKRKV peptide, we tested the fluorescein (FITC)
labeled NLS (FITC-NLS) in selected ovarian cancer cell line CP70, which is platinum-resistant.
The CP70 cells were incubated with FITC-NLS peptide for 72h, and the cells were examined under
a confocal microscope. The results are presented in Figure 9. Figure 9A represents the phasecontrast confocal image of CP70 cells, and Figure 9B shows the FITC-NLS (green) penetration
into the CP70 cells., Figure 9C shows the nucleus stained with DAPI (blue), and Figure 9D is the
overlay of B and C images. Figure 10 shows a zoom-out picture of the CP70 cell line. All cells
were successfully penetrated by FITC-NLS conjugate (Figure 10B). Based on these studies, it is
evident that the FITC-NLS peptide successfully penetrated the nuclear and cellular membrane.
These encouraging results confirm the utility of NLS-based as a drug delivery platform.
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Figure 9. Confocal images of CP70 cells incubated with NLS peptide: (A) phase-contrast
image, (B) fluorescence image of the same cells with FITC-NLS peptide, (C) nuclei of the cells
with DAPI, (D) overlay of B and C.

B

A

C

50 μm

D

Figure 10. Confocal images of a large area of CP70 cells incubated with NLS peptide: (A) phasecontrast image, (B) fluorescence of cells with FITC-NLS peptide, (C) nuclei of the cells stained
with DAPI, (D) overlay of A, B and C.
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Platinum-based drugs are used in treatments of several human malignancies, including
ovarian cancer (OC). In order to evaluate the cytotoxic properties of Pt-NLS, we tested the hybrid
in selected six OC cell lines that differ in histotypes, genomic features, and resistance to platinum64,
90-92

. All results were compared to carboplatin, a structurally similar type of platinum complex

currently used in the clinic, as well as to the NLS peptide without platinum and to NLS-free
complexes. The results are presented in Figure 11. The IC50 values of Pt-NLS hybrid and
carboplatin were determined for each cell line and are presented in Experimental Section (Figures
S19-S30). Pt-NLS hybrid demonstrated higher cytotoxicity as compared to carboplatin in all cell
lines tested. The most pronounced cytotoxic effect of Pt-NLS was observed in A2780, a platinumsensitive cell line, where a 60% decrease in viability was observed for Pt-NLS, as compared to
only 25% for carboplatin. In CP70 cell line, which is platinum-resistant and isogenic to the A2780
cell line, showed a 40% decrease in viability for Pt-NLS and 30% for carboplatin. Other Ptsensitive cell lines tested included TOV21G and ES2. The Pt-NLS reduced the viability by 50%
in TOV21G and 30% in ES2, as compared to 40% and 20% for carboplatin, respectively. For other
platinum-resistant cell lines, SKOV3 and OV90, the viability decreased by 50% and 45%, while
for carboplatin by 40% and 35%, respectively. Free azide and alkyne complexes demonstrated the
superior cytotoxic effect in all tested cell lines. The fragmentation profile from HRMS suggests
faster carboxylate ligand exchange with water and quicker release of the activated cisplatin.
However, a poor aqueous solubility of the complexes hampers their biological applications. As a
result, suspensions of both complexes had to be used in all in vitro experiments. On the other hand,
the superior solubility of the Pt-NLS hybrid over 50 mg/ml, compared to cisplatin (1 mg/ml) and
carboplatin (10 mg/ml), makes it much more desirable drug candidate.
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Figure 11. Viability of platinum-sensitive (left) and resistant (right) cells after 72 h incubation
with Pt-NLS hybrid and controls. The purity of the Pt-NLS hybrid was 87%. Each column
represents the mean and standard deviation of N = 3 and p < 0.005. The concentrations are
constant in each cell line and are as follows: 24.6 μM (A2780), 52.8 μM (CP70), 56.6 μM (TOV21G), 56.6 μM (SKOV3), 18.4 μM (ES-2), 59.0 μM (OV-90). Abbreviations: Carboplatin
(Carbpt), Complex-Pt (Cplx-Pt). Concentrations of Pt-NLS for each cell line were chosen based
on the results from IC50 studies.
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Table 1. Viability of Pt-sensitive and Pt-resistant cells after incubation with Pt-NLS hybrid for 72
h. Cells witout any treatment (blank), incubation with NLS peptide, and carboplatin were used as
controls.

% Viability

Cell line
Concentration [μM]
Blank
NLS
Carboplatin
Pt-NLS hybrid
Cplx-Pt-Alkyne
Cplx-Pt- Azide

A2780
24.6
100.0
99.0
75.0
40.0
20.0
10.0

CP70
52.8
100.0
80.0
70.0
60.0
28.0
16.0

TOV21G
56.6
100.0
82.0
60.0
50.0
33.0
34.0

SKOV3
56.6
100.0
82.0
60.0
50.0
24.0
19.0

ES2
18.4
100.0
99.0
80.0
70.0
40.0
20.0

OV90
59.0
100.0
100.0
65.0
55.0
40.0
36.0

As a proof of concept, we investigated if the Pt-NLS hybrid indeed leads to the formation
of Pt-DNA adducts in the nucleus. To this end, we determined the Pt (II) content in the isolated
DNA. We used two cell lines A2780 and CP70, that were treated with Pt-NLS for 72 hours. The
DNA was extracted from the cells, and its concentration was determined using the nanodrop, while
the platinum concentration was established with atomic absorption spectroscopy (AAS). The ratio
of platinum to DNA base pairs was found to be about 1:244 in A2780 cells and 1:114 in CP70
cells. Assuming that there are approximately ten base pairs per turn in the DNA helix, it was
estimated that the platinum complex was bound every 20th turn in the A2780 cell line and every
10th in CP70 cells. However, since the above test was performed on whole cellular DNA, including
mitochondrial, the true Pt:DNA ratio might even be higher. The above test directly confirms that
Pt-NLS effectively shuttles Pt(II) into the nucleus.
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5.5 Conclusions.
In summary, we report the synthesis and biological evaluation of carboplatin-like
complexes bearing azide and alkyne functionalities. We also report the synthesis and
characterization of the Pt-NLS hybrid. The hybrid successfully penetrates the cellular, and nuclear
membranes, thus, delivering platinum complexes into the nucleus. In addition, Pt-NLS showed
higher cytotoxicity than clinically relevant carboplatin while tested using platinum-sensitive and
platinum-resistant OC cell lines. The combination of high solubility and biological activity of the
Pt-NLS hybrid, as well as excellent transport properties of the NLS peptide, suggest a high
therapeutic potential of the Pt-NLS platform. Moreover, the Pt-complexes with alkyne and azide
ligands might find use in other transport systems, such as nanoparticles, or solid supports, which
extends their applications. Such conjugates could form the basis for other Pt (II) delivery methods.
Future studies may include in-vivo evaluation of Pt-NLS hybrid. A half-life experiment will
provide important information about drug stability under physiological conditions, while the
therapy study will provide the biodistribution and cytotoxic profile of the Pt-NLS system. Since
an enzymatic degradation of the peptide might be an issue, modified NLS peptides could be used
as targeting ligands.

Furthermore, the therapeutic applications of Pt-NLS. Can be extended to

cancer models other than ovarian. Since Pt-NLS hybrid has an amphiphilic character with a
hydrophobic platinum complex and hydrophilic NLS peptide, examining the self-assembly
properties of Pt-NLS towards micelle formation might allow the development of a new targeted
nanoparticle-based delivery system. Finally, radioactive trackers could be used to visualize the
cellular translocation of Pt-NLS hybrid, providing insights into organellar distribution of the
therapy.
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5.6 Experimental section:
5.6.1 General experimental procedures
Chemicals were purchased from Acros Organics: potassium carbonate 99%, sodium
hydride

60%

in

mineral

oil,

diethyl

methylmalonate

99%,

silver

nitrate,

cis-

dichlorodiamineplatinum (II) 99%, 5-hexynoic acid 97%, copper (I) iodine 99.995%; Alfa Aesar:
propargyl bromide 97%, (80% in toluene), 6-chloro-1-hexyne 98%, 1,6-dibromohexane 97%,
ninhydrin 99%; Fisher Scientific: uranine powder 40%, sodium azide, L-ascorbic acid, phenol,
sodium hydroxide; Chem-Impex INT’L INC.: 6-bromohexanoic acid 99.2%,
Chemicals for solid-phase peptide synthesis (SPPS) were purchased from Chem-Impex
INT'L INC.: Fmoc-L-Pro 99.44%, Fmoc-L-Val 4-alkoxybenzyl alcohol resin (0.332 meq/g) and
Nα-Fmoc-Nω-Pbf-L-Arg 99.1%, triisopropylsilane (TIPS); Acros Organics: Nα-Fmoc-Nε-Boc-LLys, ANASPEC INC.: 2-(1H-Benzotriazole-1-yl)-1,1,3,3-tetramethyluronium tetrafluoroborate
(TBTU); Alfa Aesar: piperidine 99%, trifluoroacetic acid 99% (TFA) and Oakwood Chemical:
N,N-diisopropylethylamine (DIPEA).
All solvents were bought and used without further purification. Fischer Scientific (ACS
grade): chloroform, ethyl acetate, methylene chloride, anhydrous ethyl ether, 2-propanol (IPA),
N,N-dimethylformamide (DMF), methanol, hexanes; Acros Organic: acetonitrile HPLC grade;
Alfa Aesar: anhydrous tetrahydrofuran (THF) and Koptec: ethyl alcohol 190 proof.
NMR spectra of all the synthetic samples were recorded on Bruker 400 MHz Ultra Shield
instrument.
LC/MS: Ultra High Performance Liquid Chromatography System Agilent Technologies 1200
series Accurate-Mass TOF LC/MS 6220.
IR: Nicolet iS10 FT-IR Spectrophotometer Thermo Scientific
AAS: Atomic Absorption Spectrophotometer AAnalyst 800 Perkin Elmer
27

HPLC: High-Performance Liquid Chromatography Agilent Technologies 1260 Infinity
Cell culture methods.
Human cancer-derived cell line A2780 and its isogenic clone CP70 were generously donated by
Professor J. A. Martignetti from Department of Genetics and Genomic Sciences, Icahn School of
Medicine at Mount Sinai, 1425 Madison Avenue, New York, NY 10029, and SKOV-3, OV-90,
TOV-21G, ES-2 were purchased from ATCC. The cell lines were cultured in Dulbecco's Modified
Eagle Medium (Sigma Aldrich) supplemented with 10% (A2780, CP70, SKOV-3,
ES-2) or with 15% (TOV-21G, OV-90) fetal bovine serum (HyClone) with L-Glutamine
(HyClone) and penicillin/streptomycin (HyClone). All cells were grown in a 5% CO2, watersaturated atmosphere at 37°C. For in vitro experiments, 3x105 cells were seeded in each 96-well
plate and pre-cultured overnight. All stock solutions of standards and drugs were prepared in water.
Figures S20 to S25 describe the determination of IC50 carboplatin for each cell line. Figures S26
to S31 describe the determination of IC50 Pt-NLS for each cell line. The concentration of all
substrates was adjusted to match the molar concentration of carboplatin. The volume of substrates
in the solution was adjusted to not exceed 10% of the media volume. After 72 hours of incubation,
media was removed, and the cell viability/cytotoxicity was evaluated using TACS MTT Cell
Proliferation assay (Trevigen) according to the manufacturer instructions and analyzed by a plate
reader (SpectraMax M3 by Molecular devices).

28

Isolation of DNA.
Cell lines type A2780 and CP70 were seeded onto a petri dish at the density of 3x10 5 cells/petri
dish and incubated for 72h according to the procedure described above. Media was removed, and
each dish was washed three times with PBS. Cells were treated with trypsin for approximately two
minutes then media was added. After centrifugation at 1250 rpm for 10 min, cells were washed
with PBS three times and centrifuged again. The whole cellular DNA was isolated using QIAamp
® DSP DNA Mini Kit (QIAGEN) according to the manufacturer's instructions. The concentration
of DNA was measured using NanoDrop 2000C Spectrophotometer (Thermo Scientific).

Confocal images.
Cell line type CP70 was seeded onto a 35mm MatTek confocal dish at the density of 3x10 5 cells
per dish and pre-cultured overnight and incubated with FITC modified NLS peptide in media for
72h. After incubation, media was removed, and the cells were washed three times with PBS
(Dulbecco's phosphate-buffered saline, Corning). Glutaraldehyde (Alfa Aesar) was added, and
after 2 hours' cells were washed three times with PBS again. DAPI was used to stain the nucleus.
The distribution of the drug was visualized by confocal microscopy (Fluoview FV10i
OLYMPUS).
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Synthesis of compound 1
All glassware was flame dried and cooled under an argon atmosphere.
All steps were carried under an argon atmosphere.
Diethyl methylmalonate 10.00g [58.5mmol] in 20ml of dry THF was
added dropwise into sodium hydride 3.51g [87.8mmol] suspension in 20ml of dry THF at 0oC.
Hydrogen gas evolution was observed. The reaction mixture was allowed to warm up to room
temperature and stirred for 30min. The reaction mixture was transferred via a cannula into a
solution of 1,6-dibromohexane 16.73ml [87.8mmol] in 30ml of dry THF. The color of the reaction
mixture changed to yellow/brown with stirring. Progress of the reaction was monitored by TLC
[hexane/ethyl acetate 9:1]. Upon completion (about 17 hours), the reaction was quenched with 5ml
of saturated ammonium chloride solution, diluted with 20 ml of water, and extracted with diethyl
ether [3x50ml]. The organic layer was dried with anhydrous sodium sulfate. The crude product
was purified by flash chromatography using solvent gradient starting with 1:0 to 9:1 hexane to
ether ratio. Afforded 11g of pure product [56% yield]. 1H NMR (CDCl3)  4.166 (q, 4H),  3.391
(t, 2H)  1.860 (m, 4H),  1.458 (m, 2H),  1.419 (s, 3 H),  1.351 (m, 2H),  1.241 (t, m overlap,
8 H). 13C NMR (CDCl3)  172.42, 61.11, 53.61, 35.37, 33.77, 32.66, 28.98, 27.89, 24.07, 19.84,
14.06 (Figure S1.). HRMS-ESI: m/z [M + H]+ calc. for C14H25BrO4 : 337.1014; found: 337.0992.
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Figure S 1. 1H and 13C NMR spectra of compound 1.

31

Synthesis of compound 2
All glassware was flame dried and cooled under an argon atmosphere.
All steps were carried under an argon atmosphere.
To a solution of sodium iodide 3.71g [24.7mmol] in 15ml of acetone,
6-chloro-1-hexyne was added 1.00ml [8.25mmol] and stirred under reflux overnight. Progress of
the reaction was monitored by NMR. Upon completion, acetone was removed under vacuum. The
remaining solid was diluted with 20 ml of water and extracted with diethyl ether [3x30 ml]. The
organic fraction was washed with brine [20 ml] then dried with anhydrous magnesium sulfate.
Afforded 1.52g of product [88.9% yield]. 1H NMR (CDCl3)  3.209 (t, 2 H),  2.226 (dt, 2H, J =
2.4 Hz)  1.960 (m, 3H),  1.647 (m, 2H). 13C NMR (CDCl3)  172.34, 84.11, 68.36, 61.13, 53.57,
34.91, 28.60, 23.33, 19.79, 18.13, 14.04.
Diethyl methylmalonate 1.00g [5.85mmol] in 20ml of dry THF was added dropwise into sodium
hydride 0.35g [87.8mmol] suspension in 20ml of dry THF at 0oC. Hydrogen gas evolution was
observed. The reaction mixture was allowed to warm up to room temperature and stirred for 30min.
6-iodo-1-hexyne 1.15g [7.28mmol] was added in one portion. The brown color of the solution was
observed. Progress of the reaction was monitored by TLC [hexane:ethyl acetate 9:1]. Upon
completion (about 17 hours), the reaction was quenched with 3 ml of saturated ammonium chloride
solution, diluted with 10 ml of water, and extracted with diethyl ether [3x20ml]. The organic layer
was dried with anhydrous sodium sulfate. The crude product was purified by flash chromatography
using solvent gradient starting with 1:0 to 9:1 hexane to ether ratio. Afforded 1.48g of pure product
[99.3% yield]. 1H NMR (CDCl3)  4.165 (q, 4 H),  2.195 (dt, 2H, J = 2.8 Hz)  1.917 (t, 1H), 
1.887-1.835 (m, 2H),  1.539 (m, 2H),  1.401 (s, 3H),  1.351 (m, 2H),  1.241 (t, 6H).
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C NMR (CDCl3)  172.34, 84.11, 68.36, 61.13, 53.57, 34.91, 28.60, 23.33, 19.79, 18.13, 14.04
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(Figure S2.). HRMS-ESI: m/z [M + H]+ calc. for C14H22O4: 255.1596; found: 255.1560.

Figure S 2. 1H and 13C NMR spectra of compound 2.
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Synthesis of compound 3
To a solution of bromide 8.11g [24.1 mmol], 1 in 75ml of DMF,
sodium azide 4.69g [72.1mmol] was added. Not all azide dissolved.
The reaction mixture was allowed to stir over the weekend. Progress
of the reaction was monitored by NMR. Upon completion, DMF was removed under vacuum at
45oC. Afforded colorless oil 7.20g, quantitative yield. 1H NMR (CDCl3)  4.173 (q, 4H),  3.239
(t, 2H),  1.831 (m, 2H),  1.574 (m, 2H),  1.406-1.245 (s,m,t, 15H). 13C NMR (CDCl3)  172.39,
61.07, 53.57,51.36, 35.33, 29.33, 28.70, 26.41, 24.07, 19.81, 14.02 (Figure S3.). HRMS-ESI: m/z
[M + H]+ calc. for C14H25N3O4 300.1926; found: 300.2019.
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Figure S 3. 1H and 13C NMR spectra of compound 3.
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Synthesis of compounds 4, 5
To a solution of azide 3 3.78g [12.6mmol] in 15ml of methanol,
sodium hydroxide 3.03g [75.8mmol] was added. A pale yellow
solution was observed. Progress of the reaction was monitored by
TLC [hexane:ethyl acetate 4:1]. Methanol was removed under vacuum. Water was added 20ml,
and an aqueous fraction was extracted with ether [3x20ml]. The organic phase was discarded. The
aqueous phase was acidified with 10% HCl and extracted with ethyl acetate [3x35ml]. The organic
phase was dried over anhydrous sodium sulfate. Afforded white solid 2.78g [90% yield]. 1H NMR
(DMSO)  12.566 (bs, 2H),  3.305 (t, 2 H),  1.700 (m, 2H),  1.512 (m, 2H),  1.301-1.159
(m,s,m, 9H). 13C NMR (DMSO)  173.63, 52.69, 50.56, 35.04, 28.86, 28.14, 25.93, 23.77, 19.64
Figure S5. HRMS-ESI: m/z [M + Na]+ calc. for C10H17N3O4 266.1117; found: 266.1136. IR
spectrum Figure S4.

Figure S 4. FTIR spectra of compound 4.
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Figure S 5. 1H and 13C NMR spectra of compound 4.
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Product 5 was synthesized by the same procedure from substrate 2.
Afforded white solid with [94% yield]
1

J=2.4Hz),



1.699

H NMR (DMSO)  12.610 (bs, 2 H),  2.730 (s, 1 H),  2.154 (dt, 2H
(m,

2H),

1.427

(m,

2H),

1.281-1.243

(m,s,

5H).

C NMR (DMSO)  173.63, 52.69, 50.56, 35.04, 28.86, 28.14, 25.93, 23.77, 19.64 Figure S7.
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HRMS-ESI: m/z [M + Na]+ calc. for C10H14O4 221.0790; found 221.0798. IR spectrum Figure S6.

Figure S6. FTIR spectra of compound 5.
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Figure S 7. 1H and 13C NMR spectra of compound 5.
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Synthesis of Pt-N3 (6) and Pt-CCH (7) complexes
To a suspension of cisplatin 101.6mg [0.338mmol] in 190 proof
ethanol 10ml, silver nitrate was added 112.2mg [0.660mmol]. A
white precipitate formed upon silver nitrate addition. The reaction
was stirred in the dark at 40-50oC until the test for silver +1 with
10% HCl was negative. Usually 1 to 2 hours. Most of the white
precipitate was removed by centrifugation. The remaining solid
was removed via syringe filter 0.2µm. The filtrate was tested for
the presence of platinum with tin (II) chloride.

To dicarboxylic acid 4 80.3mg [0.330mmol] solution in 2ml of ethanol, sodium hydroxide 26.4mg
[0.660mmol] in 2 ml of ethanol was added. After 5 minutes of stirring, filtrate containing activated
platinum from the first step was added dropwise. Some white precipitation was observed. Stirred
at room temperature over 2 hours. Progress of the reaction was monitored by HRMS due to poor
solubility of substrate in DMSO and methanol. Solid was removed by centrifugation and washed
twice with methanol 5ml and once with ether 20 ml Afforded white powder 66.7mg [43%yield].

Product Pt-N3 complexes: No NMR due to poor solubility. HRMSESI: m/z [M + H]+ calc. for C10H21N5O4Pt 471.1320; found
471.1313, Figure S10. IR spectrum, Figure S8.
Product Pt-CCH complexes: Afforded off white powder 32.0mg
[39.4%yield]. No NMR due poor solubility. HRMS-ESI: m/z [M + H]+ calc. for C10H18N2O4Pt
426.0993; found 426.0973, Figure S13. IR spectrum, Figure S9.
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Figure S 8. FTIR spectra of Pt-N3 complex 6.

Figure S9. FTIR spectra of Pt-CCH complex 7.
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Figure S10. HRMS of Pt-N3 complex 6.

Figure S11. HRMS of Pt-CCH complex 7.

42

General procedure for synthesis of precursor for Pt-NLS hybrid (peptide 1), Pt-NLS hybrid
(peptide 2) and NLS-FITC (peptide 3).

Peptide sequence PKKKRKV

Precursor for Pt-NLS hybrid (peptide 1)

The standard SPPS method has been employed to synthesize PKKKRKV peptide. Briefly,
5g of Fmoc-L-Val 4-alkoxybenzyl alcohol resin (0.332 meq/g) were soaked in DMF 25ml for 1hour prior to use. Deprotection of Fmoc protecting amine group was carried with 20%
piperidine/DMF solution 5 min followed by 20 min cycle. Upon completion, the resin was washed
for 1min with each solvent as follows: DMF, IPA, DMF, IPA, DMF, IPA, DMF, DMF. Kaiser test
was performed, and if positive, coupling was performed overnight. Standard coupling conditions:
Wang resin 1.65mmol, Fmoc amino acid 3.3mmol, TBTU 3.3mmol, DIPEA 6.6mmol. DMF 10ml.
The amino acid was dissolved together with TBTU in DMF then DIPEA was added. The resulting
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solution was transferred to a reaction vessel and shaken overnight. The next day resin was washed
for 1 min with DMF, IPA, DMF, and IPA. Then Kaiser test was performed again. If negative,
another deprotection cycle started, followed by coupling of subsequent amino acid. If the Kaiser
test was positive coupling procedure was repeated.
The N-terminal amino acid was derivatized with either 6-azido-hexanoic acid1 or 5hexynoic acid by the same coupling procedure. Peptide 1 was synthesized via click reaction.
Briefly, to 0.315mmol of derivatized peptide, 0.631mmol of solid copper iodide was added,
followed by 0.631mmol of 4 and ascorbic acid 0.631mmol in 5 ml of deoxygenated 20%
piperidine/DMF solution. Brown solution formed while shaking. Any exposure to air caused a
color change to green. Therefore, all solvents were degassed by passing argon gas through the
solvent for at least 30 min. Speed of reaction, when exposed to air, decreases drastically, probably
due to oxidation of Cu1+ to Cu2+.

Progress of the reaction was monitored by HRMS. Upon

completion, the resin was washed for 1 min with 5ml of DMF, IPA, DMF, Methanol,
Dichloromethane, Methanol, and diethyl ether. Cleavage of peptide 1 from the resin was achieved
with a solution of TFA/TIPS/H2O ratio 95/2.5/2.5 over 3 hours. The crude peptide was precipitated
out in cold diethyl ether, washed 3 times with cold ether then dried under vacuum. The crude
product was lyophilized then purified by HPLC. For analytical purposes, Agilent XDB-C18 5µm
4.6-150mm column was used. For purification purposes, Agilent Zorbax RX-C8 5µm, 4.6-250mm
was used. 1-35% solvent gradient over 25min of water/acetonitrile/TFA (95/5/0.01%) and
acetonitrile/water/TFA (95/5/0.01%). Fractions containing pure product were collected and used
in the synthesis of Peptide 2. HRMS-ESI: m/z [M + H]+ calc. for C56H102N17O13 1220.7843; found
1220.7867, Figure S13. IR spectrum, Figure S12, and HPLC analysis, Figure S14.
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Figure S 2. FTIR spectra of precursor for Pt-NLS hybrid (peptide 1).

Figure S 13. HRMS of precursor for Pt-NLS hybrid (peptide 1).
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Figure S 14. HPLC analysis of precursor for Pt-NLS hybrid (peptide 1).
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Pt-NLS hybrid (peptide 2)

Cisplatin 12.3mg (0.041mmol) was suspended in 0.5ml of water, 13.2mg (0.079mmol) of
silver nitrate in 0.5ml of water as added. The reaction mixture was stirred in the dark at 40-50oC
until the test for silver +1 with 10% HCl was negative. Usually 1 to 2 hours. Most of the white
precipitate was centrifuged off, and the remaining solid was removed via syringe filter 0.2µm. The
aqueous filtrate was tested for the presence of platinum with tin (II) chloride.
Peptide 1 23.8mg (0.0194mmol) was dissolved in 1 ml of water. Aqueous sodium
hydroxide was added 1.56mg in 0.5 ml of water. The filtrate containing activated platinum was
added dropwise to the sodium salt of peptide 1. The reaction was allowed to stir at room
temperature over 2 days. Progress of the reaction was monitored by HRMS. The crude product
was purified by HPLC following the same protocol as Peptide 1. The pure product was tested in
vitro. HRMS-ESI: m/z [M + H]+ calc. for C56H108N19O13Pt 1448.7943; found 1448.7873, Figure
S16. IR spectrum, Figure S15, and HPLC analysis, Figure S17.
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Figure S 15. FTIR spectra of Pt-NLS hybrid (peptide 2)

Figure S 16. HRMS of Pt-NLS hybrid (peptide 2).
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Figure S 27. HPLC analysis of f Pt-NLS hybrid (peptide 2).

49

NLS-FITC (peptide 3)

6-azido-hexanoic acid derivative of the NLS peptide obtained from synthesis of peptide 1 was
coupled via click reaction with propargyl fluorescein93. Briefly, to 0.043mmol of resin with
modified NLS, 0.017mmol of solid copper (I) iodide was added, followed by 0.172mmol of
propargyl fluorescein and ascorbic acid 0.0.017mmol in 3 ml of deoxygenated 20%
piperidine/DMF solution. Brown solution formed with shaking. Any exposure to oxygen caused a
color change to green. Progress of the reaction was monitored by HRMS. Upon completion, the
resin was washed for 1 min with 5ml of DMF, IPA, DMF, Methanol, Dichloromethane, Methanol,
and diethyl ether. Cleavage of NLS-FITC from the resin was achieved with a solution of
TFA/TIPS/H2O ratio 95/2.5/2.5 over 3 hours. The crude peptide was precipitated out in cold
diethyl ether, washed 3 times with cold ether then dried under vacuum. After desalting and
lyophilization product was used directly for the confocal imaging study. Peptide 3. HRMS-ESI:
m/z [M + H]+ calc. for C69H102N17O14 1392.7792; found 1392.7780, Figure S19.
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Figure S 18. HRMS of NLS-FITC (Peptide 3).
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5.7 Appendix
Determination of IC 50 of the Carboplatin and Pt-NLS complexes.
The cell culture method was previously described (see page 28).
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Figure S 19. Determination of IC50 of carboplatin for CP70 cell line.
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Figure S 20. Determination of IC50 of carboplatin for A2780 cell line.
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Figure S 21. Determination of IC50 of carboplatin for OV-90 cell line.
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Figure S 22. Determination of IC50 of carboplatin for ES-2 cell line.
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Figure S 23. Determination of IC50 of carboplatin for TOV-21G cell line.
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Figure S 24. Determination of IC50 of carboplatin for SKOV-3 cell line.
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Figure S 25. Determination of IC50 of Pt-NLS for CP-70 cell line.
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Figure S 26. Determination of IC50 of Pt-NLS for A2780 cell line.
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Figure S 27. Determination of IC50 of Pt-NLS for OV-90 cell line.
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Figure S 28. Determination of IC50 of Pt-NLS for ES-2 cell line.
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Figure S 29. Determination of IC50 of Pt-NLS for TOV-21G cell line.
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Figure S 30. Determination of IC50 of Pt-NLS for SKOV3 cell line.
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6. CHAPTER III. A pH-SENSITIVE NANOPARTICLE SYSTEM FOR TARGETED
DELIVERY OF Pt (II) THERAPY TO OVARIAN CANCER.
6.1 Introduction.
The importance of platinum (II) based therapy has been previously described in chapter I
and II. Briefly: platinum (II) therapy, e.g., cisplatin, carboplatin, and oxaliplatin, is broadly used
to treat many malignancies, including testicular, bladder, or ovarian cancer64. Ovarian cancer is
usually diagnosed at a late disease stage and is the leading cause of gynecologic cancer death94-95.
Gold standard treatment consists of debulking surgery combined with platinum/taxane
combination therapy. Although initial response rates are ~70-80%, recurrence rates resulting from
platinum resistance are high, leading to overall reduced survival rates94, 96. Pt (II) complexes bind
to nuclear DNA, interfering with DNA duplication and transcription, which eventually induces
cancer cell apoptosis15, 65. Although Pt (II) complexes are among the most potent anti-cancer agents
used in the clinic, severe side effects compromise the benefit of platinum therapy67. Therefore, low
clinical dosages of Pt (II) are used, often leading to subtherapeutic intracellular concentrations of
the drug. The insufficient DNA damage and activation of DNA repair mechanisms, such as
nucleotide excision repair (NER) pathway responsible for platinum-DNA adduct removal, is
considered the primary mediator of platinum resistance66, 97.
Nanoparticles (NPs) offer unique shielding effects and sustained release that can
potentially diminish severe side effects of highly toxic agents98. NPs accumulate in the tumor's
interstitium due to impaired tumor vasculature, the phenomenon known as enhanced permeability
and retention (EPR) effect99, also referred to as passive targeting. Passive targeting can be
enhanced with an active targeting approach, where ligands are implemented onto the NP's surface,
enhancing the NPs uptake by cancer cells via receptor-mediated endocytosis100. NP-based delivery
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of platinum agents has been previously explored101, including liposome102-107, polymeric108-109, or
chitosan-based110 NPs. Also, biological111 or inorganic carriers112-113 have been reported. However,
limitations to these systems exist, including low cellular uptake, uncontrollable drug release, or
inadequate efficacy, hampering the translational advancement of the NPs to the clinic114-115.
Recent developments in NP design seek stimuli-responsive "smart" building blocks sensitive
to a tumor's microenvironment, such as altered redox potential, enzyme upregulation, hypoxia, or
acidic pH, to enhance the NP's functions116-117. Some examples include pH-induced disruption of
NPs for "on-demand" drug release118-121, or pH-promoted charge conversion to enhance the NPs
uptake122-124. Also, chemical mediators such as glutathione125, as well as enzymes such as
metalloproteinases126-128, hyaluronidase129, or cathepsin B130, have been proposed to trigger the
disintegration of NPs and drug release.
Aptamers also referred to as chemical antibodies, are short single-stranded nucleic acid
sequences that fold into secondary or tertiary shapes and offer exceptional molecular
recognition131-134. The target binding characteristics of aptamers prompted their use in place of
conventional antibodies, primarily due to their small size, ease of chemical synthesis, the flexibility
of chemical modification, and long-term storage stability. Still, bare oligonucleotides are prone to
natural degradation by nuclease enzymes present in the circulation and often exhibit short in vivo
half-lives. Chemical modifications of the nucleobases have partially addressed these limitations,
but these changes can distort the aptamers' tertiary shapes and affect their target recognition
characteristics132.
One of the most common surfactants used to prolong the stability of the NPs in serum is
polyethylene glycol (PEG), as PEG-coated nanocarriers can evade the mononuclear phagocyte
system (MPS) in the circulation

47, 135

. PEG is a non-ionic hydrophilic polymer with repeating
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ethylene ether units and provides a so-called "stealth" coating that diminishes the charge-based
interactions of PEGylated nanostructures with plasma proteins47. However, studies have shown
that the cellular uptake and endosomal escape of PEGylated NPs are suppressed due to the steric
hindrance conferred by PEG136-138. Thus, PEGylated systems convertible in the tumor's
microenvironment are of great interest. The nanoemulsions with metalloproteinase-sensitive PEG
coating139, or pH-responsive micelles of PEG-siRNA140 and PEG-acrylamide, PEGphosphatidylethanolamine conjugates141-143 have been proposed thus far to improve the NP's
translocation into the cell.
Herein, we report a pH-responsive PEGylated NP system with PLGA-Pt (II) core for aptamer
(Apt)-based targeting of OC. The proposed Apt-PLGA-Pt NP belongs to the second generation
slow-releasing NPs, which are based on biocompatible and biodegradable PLGA polymer144.
PLGA exhibits a wide range of erosion times, has tunable mechanical properties, and, importantly,
is an FDA-approved polymer145. PLGA has been extensively studied for the delivery of small
molecules, proteins, and other macromolecules in commercial use and in research146. At present
many PLGA-based formulations are at the pre-clinical stage146-147. Importantly, and to the best of
our knowledge, a pH-responsive targeting mechanism in a PLGA/PEG NP system proposed herein
to deliver Pt (II) therapy has not been previously reported.
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6.2 Synthetic strategy and rationale.
Characterization of phospholipid-hydrazone-PEG, phospholipid-Apt conjugates, and
PLGA-Pt (II) hybrid. The Apt-PLGA-Pt NP is presented in Figure 13. The active targeting
module is shown in Figure 13 (top). The pH-sensitive phospholipid-hydrazone-PEG conjugate was
formed from PEG2000-aldehyde and DSPE-phospholipid-hydrazine precursors, and the reaction
was monitored by 1H and spectroscopy (Appendix Figure 21). The synthesis of phospholipidhydrazone-PEG is described in Figure 20 (Appendix). The NMR spectra demonstrate the
disappearance of the CHO signal from the aldehyde at 9.8 ppm, suggesting the formation of the
hydrazone bond between the PEG-aldehyde and the phospholipid-hydrazine (Appendix Figure
24).
The synthesis of phospholipid-Apt conjugate followed a standard EDC coupling chemistry
between an amine-terminated Apt and a carboxylate-terminated DPPE phospholipid. We used the
DNA Apt against Mucin1 (MUC1)132, a glycoprotein present on the surface of normal epithelial
cells but overexpressed by at least 10-fold in OC cells148. The final DNA content in the
phospholipid-Apt conjugate was quantified and determined to be 46.7% by mass, corresponding
to an ~ 1:31 molar ratio of DNA Apt to the DPPE phospholipid. In order to validate the targeting
strategy, we evaluated Mucin 1 expression in OC cells. MUC1 was quantified using the ELISA
test, and the results were compared to immortalized ovarian surface epithelial (IOSE) cells. The
results are presented in Figure 12. Mucin 1 expression in TOV21G, OV90, SKOV3, CP70, and
OVCAR3 is 10, 1.85, 5.34, 4.61, and 1.32 times higher in these cells when compared to Mucin 1
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content in IOSE cells. Two cell lines had a lower concentration of Mucin 1, and these included
A2780 (0.56×) and ES2 (0.07×) cells.

Figure 12. ELISA test results for mucin 1 presence in OC cell lines.
The PLGA-Pt (II) hybrid was formed by the method developed previously by our group for Pt
(II)-lipophilic carboxylates (see Chapter II 5.6)149. The coordination of PLGA-carboxylates to Pt
(II) center resembles a configuration of carboplatin and is expected to follow the exact mechanism
of action. Activation of the Pt(II) complex involves acid hydrolysis with a successive displacement
of two monodentate carboxylates, initiated with a ring-opening step, followed by a complete loss
of ligand150-151. This process is pH sensitive, and at high acidity, the first step is ten times faster
than the second, while at low acidity, this difference is four-fold152. The final active species is cis[Pt(NH3)2(H2O)2]2+ that is capable of entering the nucleus via electrostatic interactions with
negatively charged DNA64. The formation of PLGA-Pt (II) hybrid was characterized with AAS
and revealed the Pt (II) concentration of 3.62 % by mass corresponding to 1:1.7 molar ratio of Pt
(II) to PLGA in the PLGA-Pt (II) hybrid), which was calculated assuming the average molecular
weight of PLGA to be 3000 Da. This ratio suggests the coordination of two PLGA monomers to
one Pt (II) center.
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Characterization of the physicochemical parameters of Apt-PLGA-Pt NPs.
The Apt-PLGA-Pt NPs were characterized with respect to their size, surface charge, stability,
and in vitro Pt (II) release. The size of Apt-PLGA-Pt NPs was examined by dynamic light
spectroscopy (DLS) and transmission electron microscopy (TEM). The hydrodynamic diameter of
the NPs studied by DLS was found to be 110 nm with a low polydispersity of 0.199. The Zeta
potential of the NPs was determined to be – 29 mV indicating good colloidal stability of AptPLGA-Pt NPs and a negative surface charge. The negative surface charge is attributed to PEG
coating and is expected to prevent the non-specific NP-protein adsorption in vivo that might lead
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Figure 13. A schematic of an active targeting module (top) and the proposed Apt-PLGA-Pt NP
platform (bottom).
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Figure 14. TEM image of negatively stained Apt-PLGA-Pt NPs (A); stability of Apt-PLGA-Pt
NPs in 10% FBS (B); in vitro Pt (II) release from Apt-PLGA-Pt NPs in PBS at 37°C (C). TEM
images were taken together with Dr. Sylwia Dragulska.
Next, we evaluated the stability of Apt-PLGA-Pt NPs in fetal bovine serum (FBS) to determine
if PEG coating prevents the opsonization of the NPs with plasma proteins and if it protects the
DNA aptamer from enzymatic degradation. FBS is a blood product that contains a variety of active
proteins and nucleases153-154, most importantly DNase I, that can lead to the digestion of nucleic
acid-containing nanostructures155. In the experiment, the Apt-PLGA-Pt NPs were mixed with 10
% FBS solution at a final NPs concentration of 600 µg/ml and incubated at 37ºC for 48 h. The size
of the NPs was measured by DLS at different time points, and the results are shown in Figure 14B.
The diameter of the Apt-PLGA-Pt NPs remained stable during the testing period. This result
indicates the absence of any NP-protein aggregates, which would include the nucleases. It suggests
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that the acid-sensitive PEG coating is capable of shielding the Apt ligand in the NP's corona, and
therefore the NPs are expected to be stable in the systemic circulation.
The in vitro Pt (II) release from the Apt-PLGA-Pt NPs was studied at three different pH values:
7.4 (physiological), 6.8 (tumor's interstitium), and 5.5 (endosomal). The degradation rate of the
PLGA polymer is pH-dependent156, which might influence the Pt (II) release from the NPs. The
initial Pt (II) payload in the Apt-PLGA-Pt NPs was determined by AAS and was found to be 1.62
wt. %. The NP solutions at the concentration of 600 µg/ml were placed in mini dialysis tubes and
incubated at 37ºC in PBS for 12 h. The solutions were collected from the dialysis tubes at predefined time intervals and quantified for Pt (II) content using AAS. The percent of Pt (II) released,
with respect to the initial Pt (II) concentration, is presented in Figure 14C. After 3 h, only 2.5 %
of Pt (II) was released at pH 7.4, 9 % at pH 6.8, and 45 % at pH 5.5. The Pt (II) release from the
NPs after 12h at pH 7.4 was lower by 14 % when compared to pH 6.8 and by 30 % versus pH 5.5,
showing a consistent trend with the earlier time point. This result suggests low Pt (II) release in
the circulation after the intravenous administration of the NPs, and heightened Pt (II) release once
the NPs translocate into the tumor space as well as into intracellular compartments. Based on these
experiments, the Apt-PLGA-Pt NP follows the characteristics of a slow-releasing system, as
expected for PLGA-based NPs, which is of high importance in the drug delivery field144.
The direct measurement of the hydrazone-PEG bond cleavage on the Apt-PLGA-Pt NP was
monitored using a fluorescamine test. The hydrolysis of the hydrazone bond yields a free amine,
and the non-fluorescent fluorescamine in the presence of free amine produces a highly fluorescent
product. To this end, the phospholipid-hydrazone-PEG2000 conjugate solutions were incubated
with fluorescamine for 15 min at pH 7.4, 6.8, and 5.5 in 96 black well plates. The result of the test
is presented in Figure 15A. It can be clearly seen that the fluorescence is higher at pH 6.8 and
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versus pH 7.4 and the highest at pH 5.5, indicating faster hydrazone bond hydrolysis with
decreasing the pH. We also monitored the fluorescence change over time (60 min) at tumoral pH
of 6.8 during the phospholipid-hydrazone-PEG2000 conjugate incubation with fluorescamine
(Figure 15B). The fluorescence increases with longer incubation times, confirming the continuous
hydrazone-PEG bond cleavage and formation of free amines in a low acidity environment.
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Figure 15. The measurement of the hydrazone bond cleavage on the Apt-PLGA NPs via
fluorescamine test. Incubation of phospholipid-hydrazone-PEG2000 conjugate at different pH (A)
and incubation of phospholipid-hydrazone-PEG2000 conjugate at pH 6.8 (B).
6.3 Biological evaluation and discussion
Hydrolysis of DSPE-PEG2000 pH-sensitive
Hydrolysis of DSPE-PEG2000 pH-sensitive
nanoparticles
min]
Cellular [Time
uptake15and
in vitro biological activity
of the NPs.atThe
of the Apt-PLGAnanoparticles
pHinteraction
6.8
Pt NPs with OC cell lines and active cellular uptake of the NPs was investigated using
fluorescence, confocal microscopy.
First, as a proof-of-concept, we compared the internalization of the Apt-modified NPs versus
non-modified NPs, to corroborate if the presence of targeting ligands leads to the enhanced
accumulation of the NPs into cells. The experiment was performed using the CP70 cell line. To
this end, we used Apt-PLGA NPs (without platinum) coated with a short version of PEG
(phospholipid-PEG350) to expose the Apt ligand onto the NP's surface. The PLGA NPs without
the Apt ligand was used as a control. The fluorescein-labeled phospholipid was added at 5 mol %
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to the NPs' coating to facilitate the optical studies. The cells were incubated with the NPs at a
concentration of 600 µg/ml for 25 min, washed with PBS, fixed, and imaged using a confocal
microscope. The images are shown in Figure 16. While control PLGA NPs (green; without the
Apt) were detected within the cells (frame A), the Apt-PLGA NPs were internalized into cells to
a much higher extent (frame B). These results suggest that the MUC1 Apt ligand accelerates the
NPs internalization into cells via receptor-mediated endocytosis.

B

A

Figure 16. Confocal images of cells incubated with PLGA NPs without the Apt (A) and Apt-PLGA
NPs (B).

D

C

Cellular uptake of Apt-PLGA-Pt NPs labeled with Cy5.5 in real-time at pH 6.8 was
investigated with a confocal microscope. The experiment was performed using A2780 cells
cultured in confocal microscope-ready Petri dishes. The cellular membrane was stained with

200 nm

200 nm

Wheat Germ Agglutinin Alexa Fluor 594 Conjugate (WGA 594 (red)). The 27-second movie of
the first 12 min after the addition of the NPs to the cells is presented in the appendix. Cellular
uptake of the NPs was apparent (green fluorescence) and consistently increased over time. After
12 min of incubation, the NPs appear to be localized within the cells and distributed throughout
the cytoplasm.
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Next, we analyzed the uptake of Apt-PLGA-Pt NPs by OC cells. The results for A2780, CP70,
SKOV3, OV90, ES2, TOV21G, and OVCAR3 cell lines are presented in Figure 17.

Figure 17. Confocal images of Apt-PLGA-Pt NPs (red) localized inside different OC Cell lines,
nucleus staining in blue. The scale bars are 5 m. Images were taken with Mina Poursharifi.
Results confirm that the Apt-PLGA-Pt NPs undergo fast endocytosis and can be used as an
efficient nanocarrier for the intracellular delivery of Pt (II) therapy.
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The in vitro NP cytotoxic effect on the cells was assessed via Alamar Blue assay. Cell lines
were seeded in 96 well plates and incubated with Apt-PLGA-Pt NPs for 72 h at a Pt (II)
concentration corresponding to IC50 values obtained for the NPs. Cell viabilities were compared
to controls of Apt-PLGA NPs without Pt, single-agent carboplatin, and no treatment (blank)
(Figure 18). Treatment with plain Apt-PLGA NPs had no significant cytotoxic effects in any of
the cell lines tested. By contrast, the Pt-loaded NPs demonstrated significant cytotoxicity in all cell
lines. The Pt-sensitive cell lines, A2780, ES-2, and TOV-21G, demonstrated the decreased
viability by 61.0, 55.5, and 34.2%, respectively. In comparison, free carboplatin at the same
concentration decreased the viability by 49.1, 43.5, and 31.0% in the same cells. The viability of
Pt-resistant cells was decreased by 59.7, 50.4, 31.8, and 61.5% in CP70, OV90, SKOV3, and
OVACR3 cells after the incubation with Apt-PLGA-Pt NPs. Carboplatin only at the same
concentration decreased the viability by 42.7, 32.0, 12.2, and 39.3%, respectively. All Apt-PLGAPt NPs treated cell lines exhibited lower viability compared to carboplatin only. The difference in
viability is: 11.9% (A2780 cells), 12.0% (ES2 cells), and 3.2% (TOV21G cells), 17.0% (CP70
cells), 18.4% (OV90 cells), 19.6% (SKOV3 cells), and 22.2% (OVCAR3 cells). This difference is
more evident in platinum-resistant cell lines with the range of 17.0-22.2%, while about 12% in
platinum-sensitive cells. The exception is the TOV21G cell line with only a 3.2% difference in
viability. The above findings suggest higher efficacy of nanoparticle platinum (II) platform when
compared to carboplatin only.
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Figure 18. Cellular viability of different ovarian cancer cell lines after 72 h incubation with AptPLGA-Pt NPs and controls. Each column represents the mean and standard deviation of N=3 and
p<0.01 all cell lines, p<0.2 in TOV-21G. The concentrations are constant in each cell line, and are
as follows: SKOV3 3.44 x 10-5M, CP70 5.28 x 10-5M, OV-90 2.95 x 10-5M, TOV-21G 2.95 x 105

M, A2780 3.08 x 10-5M, OVCAR3 3.08 x 10-5M, ES-2 3.44 x 10-5M.
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Table 2. Cellular viability of different ovarian cancer cell lines after 72 h incubation with AptPLGA-Pt NPs and controls. Control 1: PLGA Nanoparticles with pH-sensitive PEG (without
aptamer), Control 2: PLGA Nanoparticles with pH-sensitive PEG (with aptamer), Nanoparticles:
Nanoparticles with pH-sensitive PEG and aptamer and PLGA-Pt.
A2780

CP70

TOV21G

SKOV3

ES2

OV90

OVCAR3

Concentration [μM]

30.8

52.8

29.5

34.4

34.4

29.5

30.8

Blank

100.0

100.0

100.0

100.0

100.0

100.0

100.0

Control 1

88.0

90.0

92.0

94.0

100.0

104.0

92.0

Control 2

102.0

95.0

99.0

94.0

106.0

88.0

104.0

Carboplatin

50.9

57.3

69.0

87.8

56.5

68.0

60.7

Nanoparticles

39.0

40.3

65.8

68.2

44.5

49.6

38.5

% Viability

Cell line

Characterization of Apt-PLGA-Pt NPs half-life and biodistribution in vivo. All in vivo
study was performed with assistance of Dr. Ying Chen from Icahn School of Medicine at Mount
Sinai. To examine the pharmacokinetic properties of the Apt-PLGA-Pt NPs, we used fluorescence
and AAS to measure the NPs concentration in blood samples collected at various time points
following the NPs administration. Lipids labeled with a near-infrared (NIR) Cy7 fluorophore were
added to the NP's coating at 5 mol.% to facilitate biological imaging. The Apt-PLGA-Pt NPs were
administered intravenously to nude mice at 0.314 mg Pt (II). The dose given to mice corresponds
to a bioequivalent cisplatin dose for patients (75 mg/m2)157. Blood samples were drawn at 5, 20,
45, and 120 min. The two-hour range of the sampling was chosen arbitrarily based on the drug
release study (Figure 14C). At physiological pH, the drug release is below 10% within the 2-hour
range. Based on these studies, the in vivo half-life of the Apt-PLGA-Pt NPs was found to be 45
min.
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Next, we evaluated the potential of Apt-PLGA-Pt NPs to target solid tumors in a pre-clinical
model of ovarian cancer. All mice were prepared according to the protocol described under
experimental section (see page 81). The Apt-PLGA-Pt NPs, at the same Pt (II) dose as in half-life
studies, were intravenously injected via tail vein into OVCAR-3 tumor-bearing nude mice. The
NPs biodistribution studies in vivo were performed using Cy7-labeled NPs and an IVIS small
animal imaging system. Untreated mice were used as a control. Twenty-four hours post-injection,
no fluorescence signal was detected in the control mouse, and a strong NIR signal was observed
at the tumor site in the Cy7-Apt-PLGA-Pt NPs injected mouse (Figure 19 top left). In addition,
after four days, the NIR signal in the tumor was still high, indicating prolonged retention of the
NPs in the tumor (Figure 19 top right).
After four days, the tumors and organs were excised and examined ex vivo by fluorescence and
AAS. Figure 21 (bottom) demonstrates fluorescence in the excised tumor as measured by regions
of interest (ROIs). The AAS measurements of Pt (II) concentration reveal the presence of 0.011
µg of Pt in the extracted tumor with the NPs, and a negligible Pt amount in control. Collectively,
these results strongly indicate that the NPs effectively translocate into tumors and are retained in
the tumor's interstitium for several days. Moreover, the Apt-PLGA-Pt NPs deliver Pt (II) therapy
directly to cancer cells in vivo.
The background biodistribution of the NPs into organs was also assessed, and the NIR images
of the organs, as well as AAS quantification of Pt (II), are presented in Figure 21 and 22. The NPs
were detected in the liver, spleen, and kidneys and in much lesser amounts in the heart and in the
lungs. No signal was detected in the brain, indicating that the Apt-PLGA-Pt NPs do not cross the
blood-brain barrier.
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Our results contrast with the biodistribution of the carboplatin in a cervical tumor mouse
model.

18

F-labeled carboplatin-like free-drug complex undergoes 95% renal clearance in just 1

hour, with a half-life of 16 min. The biodistribution study indicates the highest concentration of
the

18

F labeled drug in kidneys, liver, skin, and lungs. However, the concentration decreases

significantly over 90 min. The tumor sample indicates over 60% loss of the radiolabel signal over
90 min.158
8.0
24 h post-injection

6.0

4.0

x107

4 days post-injection

0.000824 µg Pt

0.0110 µg Pt

Figure 19. The images of NPs biodistribution in vivo (top) in an ovarian cancer mouse model and
excised tumors (bottom) from an NP-injected mouse (left) and a control mouse (right).
6.4 Conclusions.
In summary, a novel pH-sensitive NP-based system for active targeting and effective Pt
(II) delivery to tumors was synthesized and characterized. The Apt-PLGA-Pt NPs demonstrated
cellular uptake across various OC cell lines, resulting in efficacy in vitro, especially in Pt-resistant
cells. Also, the in vivo studies confirmed the suitability of the platform for tumor targeting and
drug delivery. These findings indicate that the Apt-PLGA-Pt NP platform can potentially be used
for Pt (II) therapy. Most importantly, the modular design of the NP allows for quick modifications,
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and the platform could easily be extended to other polymeric or lipophilic NP-based systems for
treatments of other cancers.
Future studies may focus on understanding the mechanism of action of the NP system. For
example, determining the organelle that is the final delivery point where the active drug is released
from the NP, the degradation profile of the NP or a long-term cytotoxicity of the platform. It would
also be interesting to determine if other anticancer drugs could be incorporated into the NP or if
the synergetic effect is observed in the combination therapy with other anticancer drugs, both NPbased and free drugs. In addition, Pt-NLS-hybrids could be included in the NP formulation to
investigate its influence on platinum loading and efficacy of the platform. Lastly, the role of MUC1 in NP uptake could be investigated on the ovarian cancer model with silenced genes responsible
for MUC-1 expression.
6.5 Experimental section.
6.5.1 General experimental procedure for in vitro study.
In vitro viability assay. Human cancer-derived cell line A2780 and its isogenic clone CP70,
as well as OVCAR3 cells, were generously donated by Professor J. A. Martignetti from the
Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, 1425
Madison Avenue, New York, NY 10029. SKOV-3, OV-90, TOV-21G, ES-2 were purchased from
ATCC. The cell lines were cultured in Dulbecco's Modified Eagle Medium (Sigma Aldrich)
supplemented with 10% (A2780, CP70, SKOV-3, ES-2) or with 15% (TOV-21G, OV-90) fetal
bovine serum (FBS, HyClone) with L-Glutamine (HyClone) and penicillin/streptomycin
(HyClone). All cells were grown in a water-saturated atmosphere at 37°C and 5 % CO2. The cells
were seeded at a density of 3x105 per well in a 96-well plate and pre-cultured overnight. The AptPLGA-Pt NPs were added at the concentrations corresponding to IC50 for each cell line and
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incubated for 72 hours. After 72 hours, media was aspirated, and cells were washed with PBS.
Next, Alamar Blue solution (10 %) of in PBS was added to each well, and the cells were incubated
for an additional 30 to 45 min. The metabolic activity of the cells was determined by measuring
fluorescence at 590 nm (plate reader Spectra Max M3 by Molecular Devices).
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6.5.2 General experimental procedures
The synthesis of precursor 1. First, beta-alanine 5.0 g (56.1 mmol) was dissolved in glacial
acetic acid (50 ml), and maleic acid anhydride 6.6 g (67.3 mmol) was added portion-wise. Next,
the solution was stirred until the formation of a white precipitate and the reaction mixture was
refluxed overnight. After that, the acetic acid was removed under reduced pressure at 40oC. The
remaining solid was suspended in chloroform (100 ml) and filtered through a silica gel pad,
followed by two additional washes with chloroform (2x100 ml). The filtrate was then condensed
and dried under vacuum, affording 5.6 g (49% yield) of a white solid.
12.35 (s,br,1H),  7.01(s,2H),  3.61 (t,2H),  2.51 (t,2H),

1

HNMR (DMSO-d6) 

CNMR (CDCl3)  172.06, 170.75,

13

134.61, 33.31, 32.41. HRMS-ESI: m/z [M+H]+ calc. for C7H7NO4: 170.0375; found: 170.0449.
The synthesis of precursor 2. 0.2000g (1.18 mmol) of precursor 1 and t-butyl-carbazide
0.2032 g (1.54 mmol) was dissolved in 15 ml of DCM and was chilled to 0oC. The initial step was
followed by the addition of 0.3172 g of DCC (1.54 mmol) in 5 ml of dichloromethane (DCM) to
the reaction mixture. The reaction was allowed to warm up to room temperature. The progress of
the reaction was monitored by TLC using a chloroform/methanol 4:1 solvent system. Upon
completion (usually 1 to 2 hours), the reaction mixture was chilled at -20oC. The white precipitate
was removed by filtration, and the filtrate was diluted with 30 ml of DCM and washed with 10%
HCL solution (3x20 ml) and brine (20 ml). The organic phase was dried over anhydrous sodium
sulfate and filtered. The crude product was purified by flash chromatography using hexane/ethyl
acetate gradient, starting with 4:1 to 0:1 solvent ratio. The product was a colorless oil, 0.3829 g
(87% yield). 1HNMR (CDCl3)  7.82(s,br,1H),  6.70(t,2H),  6.62(s,br,1H)  3.86(t,2H),  2.59
(t,2H),  1.44(s,9H), 13CNMR (CDCl3)  172.43, 169.31, 155.34, 81.95, 33.81, 32.29, 28.08.
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The synthesis of precursor 3. 0.2828g (1.35 mmol) of 2 was dissolved in 10 ml of 20%
solution of TFA in DCM and stored overnight. Next, the reaction mixture was condensed under
reduced pressure and diluted with 3 ml of DCM until the white product precipitated out. The
product was chilled in the freezer at -20oC for ~ 2 hours and centrifuged at 4000 rpm for 5 min at
4oC. The white solid was washed with cold DCM (2x1.5 ml) and then dried under the vacuum.
The product was a white solid, 0.1839 g (74.3% yield). 1H NMR (D2O)  6.87(s,2H),  3.84(t,2H),
 2.65 (t,2H), 13C NMR (D2O)  172.56,171.38, 33.54, 31.98. HRMS-ESI: m/z [M+H]+ calc. for
C7H9N3O3: 184.0644; found: 184.0719.
The synthesis of precursor 4. 0.0196 g (2.34 µmol) of DSPE-thiol was dissolved in 5 ml of
dry chloroform. Next, 0.0069g (2.34 µmol) of 3 was added, followed by 0.100 ml of triethylamine.
The reaction mixture was allowed to stir at room temperature for 4 hours. The progress of the
reaction was monitored by NMR. Upon completion, the solvent and triethylamine were removed
under reduced pressure. The crude product was dissolved in a minimum amount of chloroform and
precipitated out with cold methanol. The product, 0.0180 g (75% yield), was a white solid. Figure
23A HRMS-ESI: m/z [M+H]+ calc. for C51H95N4O12PS: 1019.6405; found: 1019.6465.
The synthesis of lipid-hydrazone-PEG2000 (5). 0.0150 g (1.47 µmol) of 4 was combined
with 0.0294 g (1.47 µmol) of O-[2-(6-Oxocaproylamino)ethyl]-O′-methylpolyethylene glycol
2000 and stirred in 3 ml of chloroform. The progress of the reaction was monitored by NMR
Figure 24. Upon completion, the solvent was removed under the vacuum. The product (5) was a
white solid at 0.0350 g (78% yield). Figure 23C.
The synthesis of the phospholipid-Apt conjugate. The MUC-1 aptamer-1,2-dipalmitoyl snglycero-3-phosphoethanolamine-N (DPPE)-Glutaryl conjugate was synthesized by standard EDC
protocol. Briefly, MUC-1 5'amine-modified aptamer was dissolved in 0.1 M PBS buffer at pH 6.8.
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Next, at least 10X excess of DPPE-Glutaryl was added, followed by the addition of EDC at the
concentration of 0.2 M. The reaction was stirred overnight, then desalted using a QIAquick
nucleotide removal kit. The final product (6) was stored at -20oC in a 20% ethanol/water solution.
The final DNA concentration in the construct was analyzed by Nanodrop.
Synthesis of PLGA-Pt (II) conjugate (7). Cisplatin 0.0652 g (217 µmol) was suspended in 5
ml of the nanopure water. Next, silver nitrate 0.0720 g (423 µmol) in 1 ml of water was added,
and the reaction mixture was heated to 60oC and stirred in the dark for 1 hour. The white
precipitate was filtered off, and the filtrate was added dropwise to 0.3000 g of PLGA (MW 10005000) dissolved in 15 ml of THF. The reaction was stirred at room temperature overnight. Next,
the solvent was removed under reduced pressure, and the remaining solid was dissolved in
acetonitrile. After centrifugation, the supernatant was condensed and added dropwise to cold
methanol. The pale brown precipitate (7) was collected and dried under vacuum, producing 0.3020
g. The Pt (II) content was quantified by AAS.
Nanoparticle synthesis. The Apt-PLGA-Pt NPs were synthesized via a nanoprecipitation
method159-160. First, 5 mg of 7 was dissolved in 2.5 ml of acetonitrile to achieve the concentration
of 2 mg/ml. Next, the PLGA-Pt (II) solution was added dropwise to the mixture of the following
lipids: MUC-1 aptamer-lipid (0.02 molar ratio to total lipids), 1 mg of DSPC/lipid-hydrazone-PEG
(5) in (7:3 molar ratio), in 5 ml of 4% ethanol at 60-70oC. The Apt-PLGA-Pt NPs were allowed to
stir for at least 2 hours, and then the NP solution was washed three times with water using vivaspin
filters (100.000 MW). The NP sample was condensed to achieve the volume ~ 1 ml and
characterized by TEM and DLS. The Pt (II) content was analyzed by AAS.
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Synthesis of PLGA- Cy5.5 conjugate. 101mg (0.00363 mmol) of PLGA-NH2 (MW 28000)
(PolySciTech) was dissolved in 2.5 ml of dry DMF and mixed with 2.6mg (0.00363 mmol) of
Cy5.5-NHS ester (Lumiprobe) in 0.5 ml DMF. Next, 10µl triethylamine was added, and the
reaction mixture was stirred overnight. After that, DMF was removed under reduced pressure, and
the crude reaction mixture was dissolved in 1 ml of acetonitrile. The product was precipitated out
with cold methanol and stored in the fridge, giving 49.7 mg (47% yield) of blue solid.
Nanoparticle synthesis for proof-of-concept studies (with Apt and short PEG 350).
Briefly, 5 mg of PLGA-Cy5.5 was dissolved in 2.5 ml of acetonitrile to achieve a 2 mg/ml
concentration. Next, the PLGA-Cy5.5 solution was added dropwise to the mixture of the following
phospholipids: MUC-1 Apt-phospholipid (0.02 molar ratio to total lipids), 1 mg of DSPC/DSPEPEG350 in (7:3 molar ratio), in 5 ml of 4% ethanol at 60-70oC. The Apt-PLGA NPs labeled with
Cy5.5 were allowed to stir for at least 2 hours, and then the NP solution was washed three times
with water in vivaspin 20 (100.000 MW), concentrated, and used directly for confocal imaging
studies.
Synthesis of and DSPE-Cy7 conjugate. 13.7mg (0.0183 mmol) of DSPE (Avanti Lipids) was
dissolved in 1 ml of dry DMF. Next, 12.5 mg (0.0183 mmol) of Cy7-NHS ester (Lumiprobe) in
0.5 ml of DMF was added to the solution, followed by 10 µl of triethylamine. After overnight
stirring of the reaction mixture, DMF was removed under reduced pressure. The product was
washed 3 times with cold acetonitrile and then dissolved in ethanol, giving 18 mg (77% yield) of
blue solid.
Nanoparticle characterization. The nanoparticles' size and zeta potential were analyzed by
dynamic light scattering (DLS) using ZetaPals (Brookhaven Instrument Corporation). The
concentrated NP solution was diluted in distilled water to obtain a concentration of 0.500 mg
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PLGA/ml. The obtained solution was measured for the hydrodynamic mean diameter and size
distribution. Each measurement was done in triplicate. The shape, surface morphology, and size
of the NPs were analyzed by transmission electron microscopy (TECNAI 200 kV TEM Fei,
Electron Optics). A droplet of the NPs was placed on a carbon-coated copper grid, forming a thin
liquid film. The samples were negatively stained with 2 % (w/V) solution of phosphotungstic acid.
In vitro drug release. The in vitro Pt (II) release studies from Apt-PLGA-Pt NPs were carried
out using the dialysis bag diffusion method148. Shortly, 500 µl of Apt -PLGA-Pt NPs was
dispensed into mini dialysis tubes (Slide-A-Lyser MINI dialysis units, Thermo Scientific), and the
tubes were placed in three separate beakers containing 600 ml of pH 7.4, 6.8, and 5.5 phosphate
buffer, respectively, with gentle stirring. The temperature of the buffers was maintained at
37 ± 1 °C throughout the experiment. Samples (three tubes) were withdrawn at definite time
intervals and analyzed for Pt (II) concentration with AAS. Drug release = Dt/D0 x 100. From the
above formulae, Dt and D0 indicate the amount of drug released from the NPs at certain intervals
and the total amount of drug in the NPs solution, respectively.
Fluorescamine test. phospholipid-hydrazone-PEG2000 were diluted with three solutions of
PBS at pH 7.4, 6.8, and 5.5, respectively, to achieve a final concentration of 1.6 mg NPs/ml. 10µl
of fluorescamine solution in DMSO (3 mg/ml) was added for each 150 µl of phospholipidhydrazone-PEG2000 solution. Each solution was then transferred into black flat bottom 96 well
plate and analyzed using a plate reader (Spectra Max M3 by Molecular devices). PBS solutions at
pH 7.4, 6.8, and 5.5, as well as PBS at pH7.4, 6.8, and 5.5 with Apt-PLGA NPs without
fluorescamine, were used as controls.

80

Cellular uptake of NPs. The PLGA-FITC NPs without Pt (II) was used in all imaging
experiments. For the proof-of-concept studies, CP70 cells were cultured in Dulbecco's Modified
Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), with L-Glutamine
(HyClone), and penicillin/streptomycin (HyClone). The cells were incubated with 600μg/mL plain
PLGA NPs, and Apt-PLGA-FITC NPs added to cell culture media for 15 min, washed with cold
PBS three times, and fixed by 2% paraformaldehyde for 20 min. The chambers were mounted onto
the confocal laser scanning microscope (Olympus Fluoview FV10i, Tokyo, Japan) with a red
channel excited at 684 nm.
For real-time uptake experiments, CP70 cells were plated in a four-well round chamber
(Greiner Bio-one) at a density of 5 × 104 cells/well. After 24 h, wheat germ agglutinin (WGA)
Alexa FluorTM488 conjugate (Invitrogen) was added to the media at a concentration of 5 μg/ml.
Next, the Apt-PLGA-Cy5.5 NPs were added to the cells. The pH of the media was 6.8. Imaging
started 5 minutes after the addition of the NPs and continued for 10 minutes. Imaging was
performed using an LSM880 inverted confocal microscope with Airyscan and FAST.
For imaging of Apt-PLGA NP distribution within the cells, the cells were plated in 8 well
chambers (Thermo Scientific™ Nunc™ Lab-Tek™ II Chambered Coverglass) at the density of
1.9×104 cells/well. After 24h, Next, the media was removed, and NucBlueTM live cell stain ready
probe TM (Invitrogen) in fresh media was added to the cells and incubated at room temperature for
30 minutes following the manufacturer's protocol. Then, cells were washed once with PBS 1X
(Corning Cellgro) and incubated with Apt-PLGA NPs in media at a pH of 6.8 for 1 h at 37°C.
Imaging was performed by LSM880 inverted live cell imaging confocal microscope with Airyscan
and FAST model.
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In vivo mouse model studies. All in vivo experiments were approved by the Institutional
Animal Care and Use Committee (IACUC) of the Icahn School of Medicine at Mount Sinai. Fiveweek-old female Nude mice (Charles River, MA), weighing 18-20g and maintained in specific
pathogen-free conditions, were used to generate the ovarian cancer tumor model and to determine
the in vivo half-life of the NPs.
In vivo OC model. 1×107 OVCAR3 cells were inoculated subcutaneously into the right hind
limbs of Nude mice (n=3). When resultant tumors reached approximately 500 mm3, as measured
using external calipers, mice were injected with Apt-PLGA-Pt-Cy7 NPs via tail vein at the
concentration of 0.314 mg of Pt (II). 24 h after the injection, in vivo fluorescence imaging, was
performed as described below. Mice were then euthanized, and subcutaneous tumors and organs
(brain, lung, liver, kidney, spleen, and heart) were collected for ex vivo fluorescence imaging and
AAS analysis.
In vivo fluorescence imaging. In vivo and ex vivo, NIRF imaging experiments were performed
using the IVIS-200 System (Xenogen, CA). To enable detection of the Cy7 labeled NPs, a 745 nm
excitation filter and 800nm emission filter were used. A field of view (FOV) of 17.6 and an
excitation time of 4 s were chosen.
AAS analysis of Pt (II) in organs. Excised organs were frozen, lyophilized, and dissolved in
aqua regia for 48 h. Next, the samples were sonicated for 24 h in a water-bath sonicator and dried
under vacuum. After that, 200 μL of water was added to each sample, all samples were centrifuged,
and the supernatants were directly analyzed by AAS (Figures 19).
ELISA test for Mucin 1 presence in OC cells. MUC1 test was purchased from Thermo
Scientific (EHMUC1). 1×107 cells of each type were harvested and washed 3x with PBS. Next,
the cells were suspended in 400 µl of a lysis buffer made of 50 mM Tris buffer, 100mM NaCl, and
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x1 of protease inhibitor cocktail (Thermo-Scientific cat.#7448). Protein extraction was performed
by sonication using the QSONICA Q500 sonicator. Six 5 second sonications were followed by 30
second cooldown time. Sonication was performed on ice. Protein extract was centrifuged at 15000
rpm for 30 min at 4oC. The supernatant was collected and stored on ice. Protein content was tested
using the Bradford protocol. Elisa test was performed according to manufacturer guidelines.
(Figure 12)
6.6 Appendix

Figure 20. Schematic of the synthetic approach to pH-sensitive PEG2000-hydrazone-phospholipid
coating of nanoparticles. (a) glacial acetic acid, maleic anhydride, (b) t-butyl carbazide, DCC,
DCM, (c) 20%TFA in DCM, (d) CHCl3, Et3N, (e) CHCl3
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Figure 21. Biodistribution study ex-vivo, nanoparticle treated (left), control untreated organs (right)

Figure 22 AAS analysis of biodistribution of a platinum drug in organs after 4 days.
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A

B

C

Figure 23. 1H-NMR spectrum of: A phospholipid hydrazine, B PEG-2000 aldehyde and C
phospholipid hydrazone-PEG2000 conjugate.
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Figure 24. Monitoring of hydrazone bond formation via 1H-NMR. Disappearance aldehyde proton
(top) vs. no signal in the final product (bottom).

Figure 25. A frame from the movie with Live imaging of nanoparticle uptake on CP70 OC cell
line. Membrane staining in green and nanoparticles in red. Images were taken with Mina
Poursharifi.
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SUMMARY
In summary, in chapter II we reported the synthesis of carboplatin like Pt (II) complexes

with functional groups suitable for click chemistry and the hybrid construct of Pt (II) complex with
an NLS peptide (Pt-NLS) designed to heighten Pt (II) transport into the cancer cell’s nucleus. PtNLS exhibited superior biological activity in vitro in the OC cell culture compared to free
carboplatin in platinum-resistant and platinum-sensitive cell lines. In addition, the formation of PtNLS hybrid markedly increased the solubility of Pt (II) complex in an aqueous media, which
presents a significant improvement with respect to clinical applications of Pt (II)-based therapy.
Moreover, the natural propensity of NLS peptide to penetrate cellular and nuclear membranes
resulted in an increased accumulation of the Pt-NLS complex into the nucleus compared to free Pt
(II), confirming successful drug delivery using the hybrid construct. Increased in vitro activity of
Pt-NLS complexes implies that incorporation of the Pt-NLS motive would be beneficial in more
complex drug delivery systems. Future applications might include the incorporation of Pt-NLS
and Pt-alkyne and azide complexes into even more complex delivery platforms that are
additionally modified with tumor-targeting ligands. One can also envision further NLS peptide
modifications that would allow peptide self-assembly into Pt-loaded NPs, such as micelles.
In Chapter III, we presented a new NP-based delivery system composed of biodegradable
polymer PLGA-Pt (II) conjugate and an aptamer-based active targeting in combination with pHresponsive phospholipid-PEG coating. The PEG coating on the NP’s surface shields aptamer
ligands in physiological pH and is removed upon pH drop around the tumor site exposing aptamers.
The pH-active coating is designed to prevent the enzymatic degradation of the aptamer ligands
while the NP is in the systemic circulation, thus extending its effective half-life and preserving the
integrity of the targeting module. The in vitro viability studies of Pt-resistant and Pt-sensitive OC
87

cell lines show the superior activity of the NPs compared to the free drug. Furthermore, live
imaging studies confirm quick cellular uptake of the NPs. Preliminary in vivo studies show NPs
accumulation in the tumor. The proposed delivery platform is highly versatile and scalable. The
polymeric core can be easily modified with other anticancer drugs while changing the aptamer
ligand to target different cellular receptors can modify targeting properties of the NP, thus allowing
applications of the NP to different cancer types. The pH-responsive coating is also adaptable and
can easily be modified to accommodate smaller or larger targeting ligands. In summary, we have
developed a flexible NP-based drug delivery platform with possible wide future applications in
anticancer therapy.
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